Defactinib Recruiting Phase 2 Trials for Pancreatic Ductal Adenocarcinoma / Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03727880Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma